Pierre Théroux

Q: What Schools Are Affiliated With Pierre Théroux

Pierre Théroux is affiliated with the following schools: Université de Montréal, University of Alberta, University of British Columbia, Dalhousie University

Pierre Théroux's AcademicInfluence.com Rankings

Pierre Théroux

Philosophy

#5501

World Rank

#8322

Historical Rank

Logic

#2769

World Rank

#3806

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Pierre Théroux's Degrees

PhD Biomedical Sciences Université de Montréal
Doctorate Medicine Université de Montréal

Why Is Pierre Théroux Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Pierre Théroux's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (1994) (3667)
ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients (2002) (3666)
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients (2002) (2245)
ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie (2007) (1962)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. (2015) (1787)
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. (2005) (1559)
Long-term use of ticagrelor in patients with prior myocardial infarction. (2015) (1399)
Aspirin, heparin, or both to treat acute unstable angina. (1988) (1106)
2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Forc (2012) (1056)
ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). (2000) (1029)
Pathophysiology of Coronary Artery Disease (2005) (993)
ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary article (2002) (893)
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials (2002) (840)
Vorapaxar in the secondary prevention of atherothrombotic events. (2012) (839)
Regional Myocardial Function during Acute Coronary Artery Occlusion and Its Modification by Pharmacologic Agents in the Dog (1974) (770)
Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. (2005) (735)
Prognostic value of exercise testing soon after myocardial infarction. (1979) (689)
Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. (1992) (671)
ACC/AHA guidelines for the management of patients with unstable angina and non‐ST segment elevation myocardial infarction: Executive summary and recommendations (2000) (606)
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2011) (595)
2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013) (590)
Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. (1999) (529)
Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. (1986) (514)
2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in c (2011) (474)
Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes (2001) (429)
2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2011) (420)
Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. (1998) (393)
Inhibition of the Sodium-Hydrogen Exchanger With Cariporide to Prevent Myocardial Infarction in High-Risk Ischemic Situations: Main Results of the GUARDIAN Trial (2000) (393)
Depression and 1-year prognosis in unstable angina. (2000) (392)
A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. (1990) (379)
Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. (1998) (374)
Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. (1996) (369)
Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention: Results of the GOLD (AU-Assessing Ultegra) Multicenter Study (2001) (360)
Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) Trial (2003) (346)
2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in (2011) (309)
Regional Myocardial Function and Dimensions Early and Late after Myocardial Infarction in the Unanesthetized Dog (1977) (308)
Aspirin Versus Heparin to Prevent Myocardial Infarction During the Acute Phase of Unstable Angina (1993) (308)
2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2013) (299)
Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. (1999) (292)
The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. (2004) (290)
Is variant angina the coronary manifestation of a generalized vasospastic disorder? (1981) (273)
Fibrinopeptide A and platelet factor levels in unstable angina pectoris. (1987) (248)
Unstable angina and progression of coronary atherosclerosis. (1983) (245)
An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. (2002) (226)
Regional Myocardial function in the conscious dog during acute coronary occlusion and responses to morphine, propranolol, nitroglycerin, and lidocaine. (1976) (226)
A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. (2001) (225)
Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and s (1999) (216)
Regional Myocardial Function in the Conscious Dog During Acute Coronary Occlusion and Responses to Morphine, Propranolol, Nitroglycerin, and Lidocaine (1976) (216)
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (2011) (214)
Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. (2006) (203)
Job strain and risk of acute recurrent coronary heart disease events. (2007) (203)
Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. (2006) (200)
Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. (1996) (193)
Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Fibrinolysis in Acute Myocardial Infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) Trial (2003) (193)
Coronary arterial reperfusion. III. Early and late effects on regional myocardial function and dimensions in conscious dogs. (1976) (192)
Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease (2003) (189)
Common Genetic Vulnerability to Depressive Symptoms and Coronary Artery Disease: A Review and Development of Candidate Genes Related to Inflammation and Serotonin (2006) (184)
Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. (2016) (179)
Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. (2004) (177)
Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary Syndromes (1998) (173)
Selective Inhibition of the Contractile Apparatus: A New Approach to Modification of Infarct Size, Infarct Composition, and Infarct Geometry During Coronary Artery Occlusion and Reperfusion (1992) (158)
A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. (1985) (153)
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study☆☆☆★ (2002) (152)
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. (2002) (152)
Comparative Sensitivity of Exercise, Cold Pressor and Ergonovine Testing in Provoking Attacks of Variant Angina in Patients with Active Disease (1982) (149)
Comparison of Primary Percutaneous Coronary Intervention and Fibrinolytic Therapy in ST-Segment–Elevation Myocardial Infarction: Bayesian Hierarchical Meta-Analyses of Randomized Controlled Trials and Observational Studies (2009) (148)
Programmed ventricular stimulation in survivors of an acute myocardial infarction. (1985) (144)
Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: results from the GUARDIAN trial. (2001) (144)
Clinical and angiographic predictors of new total coronary occlusion in coronary artery disease: analysis of 313 nonoperated patients. (1984) (144)
Factors influencing the long-term prognosis of treated patients with variant angina. (1983) (143)
Depression, C-reactive Protein and Two-year Major Adverse Cardiac Events in Men after Acute Coronary Syndromes (2007) (138)
Technetium-99m sestamibi tomography in patients with spontaneous chest pain: correlations with clinical, electrocardiographic and angiographic findings. (1991) (134)
Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. (2005) (133)
Long-term prognosis of patients with variant angina. (1987) (129)
Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction. (1990) (128)
The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. (2011) (122)
Circadian variation in variant angina. (1984) (122)
Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB). (1997) (121)
Prognostic significance of newly acquired bundle branch block after aortic valve replacement. (2004) (119)
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. (2005) (119)
Ergonovine testing to detect spontaneous remissions of variant angina during long-term treatment with calcium antagonist drugs. (1981) (117)
Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. (1995) (116)
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. (1995) (114)
Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study. (2003) (109)
Initial Experience With a Direct Antithrombin, Hirulog, in Unstable Angina Anticoagulant, Antithrombotic, and Clinical Effects (1993) (109)
Early postinfarction ischemia: clinical, angiographic, and prognostic significance. (1987) (109)
Comparison of clinical variables and variables derived from a limited predischarge exercise test as predictors of early and late mortality after myocardial infarction. (1985) (108)
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. (2006) (108)
Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in NonST-Segment Elevation Acute Coronary Syndromes (2007) (107)
Provocative testing with ergonovine to assess the efficacy of treatment with nifedipine, diltiazem and verapamil in variant angina. (1981) (105)
Hemodynamics and coronary flow following diltiazem administration in anesthetized dogs and in humans. (1980) (105)
Clinical outcomes of bivalirudin for ischemic heart disease. (1999) (104)
A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. (1994) (99)
Myocardial reperfusion in the pig heart model: infarct size and duration of coronary occlusion. (1987) (98)
Ergonovine testing in a coronary care unit. (1980) (97)
Benefits and Safety of Tirofiban Among Acute Coronary Syndrome Patients With Mild to Moderate Renal Insufficiency: Results From the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial (2002) (97)
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. (2016) (96)
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. (2003) (96)
Determinants of hemorrhagic infarcts. Histologic observations from experiments involving coronary occlusion, coronary reperfusion, and reocclusion. (1990) (94)
Clinical and Angiographic Factors Associated With Coronary Artery Disease Progression of Coronary Artery Disease (1984) (91)
Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. (1999) (91)
Quantitative Angiographic Morphology of the Coronary Artery Lesions at Risk of Thrombotic Occlusion (1992) (88)
Spontaneous remission is a frequent outcome of variant angina. (1983) (86)
Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events. (1999) (85)
Glycoprotein IIb/IIIa Receptor Blockade Improves Outcomes in Diabetic Patients Presenting With Unstable Angina/Non–ST-Elevation Myocardial Infarction: Results From the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study (2000) (84)
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina (2001) (83)
Endothelial Progenitor Cells Bind and Inhibit Platelet Function and Thrombus Formation (2009) (80)
Prevalence and non-invasive predictors of left main or three-vessel coronary disease: evidence from a collaborative international meta-analysis including 22 740 patients (2012) (78)
Early noninvasive identification of failed reperfusion after intravenous thrombolytic therapy in acute myocardial infarction. (1998) (78)
Provocative Testing with Ergonovine to Evaluate the Efficacy of Treatment with Calcium Antagonists in Variant Angina (1979) (75)
Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. (2008) (73)
Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. (2005) (72)
Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. (2000) (72)
Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes. (1995) (71)
ACCF/AHA Focused Update 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non–ST-Elevation Myocardial Infarction (2011) (71)
Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery. (1996) (71)
ACCF / AHA Focused Update 2012 ACCF / AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina / Non – ST-Elevation Myocardial Infarction ( Updating the 2007 Guideline and Replacing the 2011 Focused Update ) (2012) (71)
Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States (2015) (71)
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. (2017) (70)
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. (2002) (70)
Clinical characteristics of patients with variant angina complicated by myocardial infarction or death within 1 month. (1982) (67)
Antithrombotic agents in coronary artery disease. (1995) (67)
Age-related differences in in-hospital mortality and the use of thrombolytic therapy for acute myocardial infarction. (2001) (67)
Requirements for Membrane Attack Complex Formation and Anaphylatoxins Binding to Collagen-Activated Platelets (2011) (65)
Favorable effects of hyperosmotic reperfusion on myocardial edema and infarct size. (1992) (65)
Aspirin, Warfarin, or the Combination for Secondary Prevention of Coronary Events in Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Surgery (2001) (61)
Coronary artery disease in young women: clinical and angiographic features and correlation with risk factors. (1978) (61)
Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients (2014) (59)
Prognostic significance of progression of coronary artery disease. (1985) (58)
B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. (2010) (56)
Plasma endothelin-1 levels in stable and unstable angina. (1993) (56)
Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. (1984) (55)
The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. (2011) (55)
Detection and assessment of unstable angina using myocardial perfusion imaging: comparison between technetium-99m sestamibi SPECT and 12-lead electrocardiogram. (1990) (55)
Effects of Thrombolytic Therapy Administered 6 to 24 Hours After Myocardial Infarction on the Signal‐Averaged ECG: Results of a Multicenter Randomized Trial (1994) (54)
Spontaneous variability of ventricular arrhythmias in patients at increased risk for sudden death after acute myocardial infarction: consecutive ambulatory electrocardiographic recordings of 88 patients. (1987) (54)
Long-term prognosis after myocardial infarction in patients with previous coronary artery bypass surgery. (1988) (54)
Intravenous diltiazem in acute myocardial infarction. Diltiazem as adjunctive therapy to activase (DATA) trial. (1998) (54)
Left ventricular ejection fraction to predict early mortality in patients with non-ST-segment elevation acute coronary syndromes. (2005) (53)
Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. (2000) (53)
Modulation of Platelet-neutrophil Interaction with Pharmacological Inhibition of Fibrinogen Binding to Platelet GPIIb/IIIa Receptor (1999) (53)
Comparison of outcome of patients with unstable angina and non-Q-wave acute myocardial infarction with and without prior coronary artery bypass grafting (Thrombolysis in Myocardial Ischemia III Registry). (1996) (52)
Assessment of activity status and survival according to the Canadian Cardiovascular Society angina classification. (2009) (51)
Genetic predictors of depressive symptoms in cardiac patients (2009) (51)
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. (2001) (50)
Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. (2010) (50)
Low-Dose Combined Therapy with Fluvastatin and Cholestyramine in Hyperlipidemic Patients (1994) (50)
S-T segment elevation and coronary spasm in response to exercise. (1981) (49)
Redefining medical treatment in the management of unstable angina. (2011) (48)
Meta-analysis of randomized trials comparing enoxaparin versus unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction. (2003) (47)
Long-term reproducibility and significance of provokable ventricular arrhythmias after myocardial infarction. (1986) (47)
Previous coronary artery bypass grafting as an adverse prognostic factor in unstable angina pectoris. (1986) (45)
Left main stenting–as a bridge to surgery–for acute type A aortic dissection and anterior myocardial infarction (2000) (45)
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. (2011) (44)
Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 2: ST-segment elevation myocardial infarction. (2011) (44)
Unstable angina: pathogenesis, diagnosis, and treatment. (1993) (43)
Previously Undiagnosed Variant Angina as a Cause of Chest Pain after Coronary Artery Bypass Surgery (1980) (43)
Geometric features of coronary artery lesions favoring acute occlusion and myocardial infarction: a quantitative angiographic study. (1999) (42)
Cell-to-cell interaction: a mechanism to explain wave-front progression of myocardial necrosis. (1989) (42)
Clinical and angiographic factors associated with progression of coronary artery disease. (1984) (42)
A randomized placebo-controlled trial to assess the efficacy of antiinflammatory therapy with methylprednisolone in unstable angina (MUNA trial). (2000) (41)
Noninvasive assessment of aortocoronary bypass graft patency using pulsed Doppler echocardiography. (1979) (40)
Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations main results of the guard during ischemia against necrosis (GUARDIAN) trial (2001) (40)
Angiographic findings after myocardial infarction in patients with previous bypass surgery: explanations for smaller infarcts in this group compared with control patients. (1985) (39)
Design features of a controlled clinical trial to assess the effect of a calcium entry blocker upon the progression of coronary artery disease. (1987) (38)
Antithrombotic properties of transdermal nitroglycerin in stable angina pectoris. (1994) (38)
Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview of Randomized Clinical Trials (2011) (37)
Acute Coronary Syndromes: A Companion to Braunwald's Heart Disease (2003) (37)
Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 1: non-ST-segment elevation ACS. (2011) (37)
Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. (2010) (36)
Avoiding interpretive pitfalls when assessing arrhythmia suppression after myocardial infarction: insights from the long-term observations of the placebo-treated patients in the Cardiac Arrhythmia Pilot Study (CAPS) (1991) (36)
Factors associated with progression of coronary artery disease in patients with normal or minimally narrowed coronary arteries. (1985) (35)
Effects of Diltiazem on Experimental Myocardial Ischemia and on Left Ventricular Performance (1983) (35)
Diltiazem and progression of myocardial ischemic damage during coronary artery occlusion and reperfusion in porcine hearts. (1987) (35)
Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). (2005) (34)
The delay to thrombolysis: an analysis of hospital and patient characteristics. Quebec Acute Coronary Care Working Group. (1998) (34)
High-performance liquid chromatographic determination of diltiazem and six of its metabolites in human urine. (1984) (34)
Hemodynamic effects of calcium ion antagonists after acute myocardial infarction. (1980) (34)
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. (2013) (33)
Pulsed Doppler Echocardiographic Study of Mitral Stenosis (1980) (33)
Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. (2015) (32)
Protection of the myocardial cell during ischemia. (1999) (32)
The delay to thrombolysis: an analysis of patient and hospital characteristics (1998) (32)
Clinical predictors of angina following myocardial infarction. (1979) (32)
Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. (2004) (31)
Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes. (2000) (31)
Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study. (2005) (31)
Angiographic and clinical progression in unstable angina. From clinical observations to clinical trials. (1995) (31)
Myocardial cell protection : a challenging time for action and a challenging time for clinical research. (2000) (31)
Influence of fibrinolysis and percutaneous transluminal coronary angioplasty on the frequency of ventricular premature complexes. (1989) (30)
A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris. (2001) (30)
Oral inhibitors of platelet membrane receptor glycoprotein IIb/IIIa in clinical cardiology: issues and opportunities. (1998) (29)
Favorable effects of orally administered digoxin on left heart size and ventricular wall motion in patients with previous myocardial infarction. (1976) (29)
Complement activity and pharmacological inhibition in cardiovascular disease. (2006) (29)
Ventricular arrhythmias during ergonovine-induced episodes of variant angina. (1984) (28)
N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. (2006) (28)
Hemodynamic effects of a single oral dose of nifedipine following acute myocardial infarction. (1980) (27)
Prognostic significance of elevated creatine kinase MB after coronary bypass surgery and after an acute coronary syndrome: results from the GUARDIAN trial. (2003) (27)
Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators. (2001) (26)
A heparin-controlled study of MK-383 in unstable angina (1994) (26)
Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial (2012) (26)
Progress in the treatment of acute coronary syndromes: a 50-year perspective (1950-2000). (2000) (24)
Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes. (2000) (24)
A pathophysiologic basis for the clinical classification and management of unstable angina. (1987) (24)
Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). (2004) (23)
Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. (2012) (23)
Unstable angina--report from a Canadian expert roundtable. (1996) (23)
Non-invasive pulsed Doppler study of mitral stenosis and mitral regurgitation: preliminary study. (1979) (23)
Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups (2006) (23)
Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. (2000) (22)
A score predicts failure of reperfusion after fibrinolytic therapy for acute myocardial infarction. (2003) (21)
Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical benefits of aspirin? (1997) (21)
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts following percutaneous transluminal coronary angioplasty. (1992) (21)
Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention. (2003) (20)
Exercise stress testing in the post-myocardial infarction patient. (1983) (20)
Loss of regional ventricular postextrasystolic potentiation after coronary occlusion in dogs. (1977) (20)
Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. (2006) (20)
Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy. (2003) (20)
Clinical and angiographic features and prognostic significance of early postinfarction angina with and without electrocardiographic signs of transient ischemia. (1991) (19)
Clinical manifestations and pathophysiology of myocardial ischemia with special reference to coronary artery spasm and the role of slow channel calcium blockers. (1982) (18)
Coronary angiographic significance of left anterior fascicular block during acute myocardial infarction. (1985) (18)
Myocardial infarction in patients with previous coronary artery bypass surgery. (1984) (18)
Five- to ten-year outcome after multivessel percutaneous transluminal coronary angioplasty. (1993) (17)
Design of a trial evaluating myocardial cell protection with cariporide, an inhibitor of the transmembrane sodium-hydrogen exchanger: the Guard During Ischemia Against Necrosis (GUARDIAN) trial (2000) (17)
Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes. (2006) (16)
Lipoprotein (a) blood levels in unstable angina pectoris, acute myocardial infarction, and after thrombolytic therapy. (1991) (16)
Antiplatelet and antithrombotic therapy in unstable angina. (1991) (16)
Left main coronary artery stenosis in young patients. (1979) (15)
Revisiting the Canadian Cardiovascular Society grading of stable angina pectoris after a quarter of a century of use. (2002) (15)
Utilization of catheterization and revascularization procedures in patients with non‐ST segment elevation acute coronary syndrome over the last decade (2005) (15)
Influence of tachycardia and arterial hypertension on infarct size in the pig. (1988) (15)
Heparin resistance in acute coronary syndromes (2007) (15)
'True' fasting serum insulin level, insulin resistance syndrome and coronary artery disease (1997) (13)
Complementary prognostic values of ST segment deviation and Thrombolysis In Myocardial Infarction (TIMI) risk score in non-ST elevation acute coronary syndromes: Insights from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-P (2009) (13)
The pre-hospital fibrinolysis experience in Europe and North America and implications for wider dissemination. (2011) (13)
Calcium antagonists. Clinical use in the treatment of angina. (1983) (13)
Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction (2016) (12)
Effects of diltiazem on atrioventricular conduction and arterial blood pressure: correlation with plasma drug concentrations. (1984) (12)
Prostaglandin E1 increases myocardial contractility in the conscious dog. (1984) (12)
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. (2013) (12)
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. (1998) (12)
Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). (2008) (12)
Design of a multicenter, double-blind study to assess the effects of prophylactic diltiazem on early reinfarction after non-Q-wave acute myocardial infarction: diltiazem reinfarction study. (1986) (11)
Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). (2003) (11)
Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infar (2009) (11)
Effect of inhibition of the Na+/H+ exchanger with cariporide on left ventricular function in acute coronary syndromes: results from the echocardiographic substudy of the GUARDIAN trial. (2004) (11)
Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline? (2007) (11)
Prognosis of variant angina patients treated with calcium antagonist drugs (1981) (10)
Demographics, treatment and outcome of acute coronary syndromes: 17 years of experience in a specialized cardiac centre. (2006) (10)
Hemodynamic, platelet and clinical responses to prostacyclin in unstable angina pectoris. (1990) (10)
Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library. (2008) (10)
Late development of left ventricular outflow tract obstruction after repair of double-outlet right ventricle. (1976) (10)
Troponin I levels in unstable angina/non-Q wave myocardial infarction patients treated with tirofiban, a glycoprotein IIb/IIIa antagonist (1998) (10)
Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction (1991) (10)
Antithrombin-III plasma activity during and after prolonged use of heparin in unstable angina. (1993) (10)
Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis). (2001) (9)
New antithrombotics. (1995) (9)
Refractory variant angina controlled with combined drug therapy in a patient with a single coronary artery. (1980) (9)
Spontaneous regression of coronary artery obstructions: incidence in 313 consecutive repeat angiograms. (1985) (9)
Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial (2017) (8)
Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease. (2001) (8)
Prevention of progression of minimal coronary lesions with a calcium channel blocker (1990) (8)
A comparative study of calcium-ion antagonists in patients with variant angina. (1980) (8)
Effects of P2Y1 receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel (2012) (8)
The systolic stress-volume relationship. (1983) (8)
Failure of ketanserin, a serotonin inhibitor, to prevent spontaneous or ergonovine-induced attacks of variant angina. (1985) (8)
Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (2009) (7)
Intracoronary infusion of superoxide dismutase and reperfusion injury in the pig heart (1990) (7)
Evaluation and risk stratification of acute coronary syndromes using a low cut-off level of cardiac troponin T, combined with CK-MB mass determination. (2004) (7)
The Past, the Present, the Future (2011) (7)
The influence of timing of surgery on mortality and incidence of mydcardial infarction following aortocoronary vein graft surgery in crescendo angina (1973) (6)
Calcium Antagonists (1983) (6)
Is progression of coronary artery disease occurring at bouts or as a continuous process? Serial cineangiographic studies in 44 patients. (1984) (6)
833-5 Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: Insights from the complement inhibition in myocardial infarction treated with angioplasty (COMMA) trial (2004) (6)
Recurrence of Prinzmetal angina seven years following aortocoronary bypass surgery: a clinical and angiographic follow-up. (1979) (6)
Classification and risk stratification of patients with acute chest pain using a low discriminatory level of cardiac troponin T (2004) (6)
A first‐in‐man study of percutaneous myocardial cryotreatment in nonrevascularizable patients with refractory angina (2009) (6)
Abstract Twenty-third annual scientific session American College of Cardiology New York, New York, February 11 to 14, 1973Local myocardial function during acute coronary occlusion in the conscious dog (1974) (5)
Antithrombotic agents in coronary artery disease. (1992) (5)
Evaluation of the Newton Pen-Pad as a tool for collecting clinical research data at the bed-side. (1996) (5)
Epoprostenol (Prostacyclin) in Unstable Angina (1988) (5)
Sulfinpyrazone decreases epinephrine-induced platelet aggregation after myocardial infarction. (1982) (5)
Improved long-term clinical outcomes in unstable angina-patients undergoing coronary angioplasty following therapy with tirofiban and heparin (1998) (5)
A prospective randomized study of propranolol versus diltiazem in patients with unstable angina (1982) (5)
Regional myocardial function early and during the healing of acute myocardial infarction (1975) (4)
Exercise testing in the early period after myocardial infarction in the evaluation of prognosis. (1984) (4)
Antithromboric agents in coronary artery disease (1992) (4)
Perspectives on acute coronary syndromes. (2005) (4)
931-111 Platelet Activation and Aggregation by Therapeutic Doses of Heparin (1995) (3)
Predictive value and safety of low level exercise tolerance testing early after acute myocardial infarction (1978) (3)
Problems related to the detection of myocardial ischemia caused by coronary vasospasm. (1986) (3)
1118-101 Congestive Heart Failure and Cardiogenic Shock Complicating Acute Myocardial Infarction Have High Mortality and Are Associated With Intense Inflammatory Response: Results From the CARDINAL Trials (2004) (3)
Coping with new challenges in acute coronary syndromes. (2006) (3)
Clinical and angiographic features of coronary artery disease in young women (1978) (3)
Evolution of regional postextrasystolic potentiation during experimental myocardial infarction (1976) (3)
A symposium: sodium-hydrogen exchange inhibition. Introduction. (1999) (3)
Gender Differences in Management of Myocardial Infarction in Quebec (1998) (2)
Coronary thrombolysis: adjuvant medical therapy. (1993) (2)
Evaluation of prognosis I year after myocardial infarction (1984) (2)
Antiplatelet drugs in the acute phase of myocardial infarction (1999) (2)
Acute non‐ST‐segment Elevation Coronary Syndromes: Unstable Angina and non‐ST‐segment Elevation Myocardial Infarction (2007) (2)
A new look at coronary angiograms: plaque morphology as a help to diagnosis and to evaluate outcome (1994) (2)
Abstract 3160: Comparison Of Primary Percutaneous Coronary Intervention and Fibrinolytic Therapy in Randomized Controlled Studies and Observational Studies: Results of Hierarchical Bayesian Meta-Analyses (2007) (2)
Non‐ST Segment Elevation Acute Coronary Syndromes: Unstable Angina and Non‐ST Segment Elevation Myocardial Infarction (2010) (2)
Platelet Function and Monitoring With Long-Term Inhibition of the Glycoprotein IIb/IIIa Receptor With Oral Antagonists (1998) (2)
Thrombosis in coronary artery disease: its pathophysiology and control (2002) (2)
Medical Decision Making in the Choice of a Thrombolytic Agent for Acute Myocardial Infarction (1999) (2)
Antithrombotic treatment of acute coronary syndromes. (1998) (2)
Whither the coronary care unit? (1987) (2)
Abstract 17121: Reduction in Total Cardiovascular Events With Long-term Use of Ticagrelor in Patients With Prior Myocardial Infarction in the PEGASUS-TIMI 54 Trial (2015) (2)
Variability in inhibition of platelet aggregation with clopidogrel and correlation with ADP-induced P-selectin expression on platelets (2002) (1)
Interaction of antagonists with the platelet GPIIb/IIIa: characterisation of two monoclonal antibodies that detect drug binding (1998) (1)
Are qualitative features of coronary artery lesions useful in predicting progression (1994) (1)
Abstract 19642: Consistent Benefit of Ticagrelor Both Early and Late in Patients With Prior MI in PEGASUS-TIMI 54 (2015) (1)
INTRACORONARY SUPEROXIDE DISMUTASE DURING THE INITIAL BURST OF FREE RADICALS (1990) (1)
Role of Diltiazem in the Treatment of Silent Myocardial Ischemia (1991) (1)
Noninvasive pulsed doppler study of mitral blood flow (1978) (1)
Coronary thrombolysis: prehospital use. (1993) (1)
Do all Q waves after coronary bypass surgery impact six-month prognosis? (2002) (1)
931-112 A Low-dose Intravenous Aspirin, Bolus Injection, Effectively Inhibits Platelet Aggregation (1995) (1)
Sinus Node Dysfunction and Sudden Cardiac Death Following Treatment with Encainide (1989) (1)
Higher Aspirin Dose is Associated with Reduced Mortality and More Serious Bleeding in Patients with Recent Cerebrovascular or Coronary Ischemic Events: Insights from the BRAVO Trial (2003) (1)
Antithrombotic agents in coronary artery disease. (1998) (1)
Abstract 569: NT-proBNP is an Important Independent Predictor of Clinical Events after Primary PCI for STEMI (2008) (1)
Maximal versus low level exercise testing after Q and non-Q wave myocardial infarction (1991) (1)
Cardiovascular findings in arterial tortuosity syndrome (2015) (1)
Determinants of Hemorrhagic Infarcts (2007) (1)
Antiplatelet Therapy in Coronary Disease: What Agent to Use, When, and How? (1998) (1)
DEPRESSION AND 1-YEAR PROGNOSIS IN UNSTABLE ANGINA (1998) (1)
Late (> 48 hr) myocardial infarction after PTCA: Clinical and angiographic characteristics of infarction related or not to the angioplasty site (2001) (1)
Serious arrhythmias during spontaneous attacks of variant angina as predictors of subsequent sudden death (1982) (1)
[Usefulness of 24-hour electrocardiographic monitoring in the treatment of patients with Prinzmetal's angina]. (1983) (1)
[The value and limits of hemodynamic monitoring of acute myocardial infarction (author's transl)]. (1978) (1)
[Objective evaluation of calcium antagonists in Prinzmetal's angina with the ergonovine test]. (1983) (1)
Hemodynamic and therapeutic effects of intravenous dopamine. (1977) (1)
Role of oxygen restoration in reperfusion-induced arrhythmias : differential effects on ventricular ectopic activity and ventricular fibrillation in the pig (1991) (1)
Pharmacologic therapy of myocardial ischemia (1992) (1)
Abstract 12776: Non-ST-segment Elevation Acute Coronary Syndromes Patients without Angiographically Detected Obstructive Coronary Artery Disease are Low-risk but Not No-risk: A Meta-analysis of 8 Trials of 37,101 Patients (2010) (1)
Medical decision making in the choice of a thrombolytic agent for acute myocardial infarction. Quebec Acute Coronary Care Working Group. (1999) (1)
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. (2001) (1)
Gender differences in risk factors of young patients hospitalized with acute coronary syndromes (1998) (0)
804-4 A Randomized, Double-blind Trial of Streptokinase Versus Placebo for the Management of Unstable Angina and Non-Q-wave Myocardial Infarction in Patients with Previous Coronary Artery Bypass Surgery (1995) (0)
Irish Cardiac Society Annual General Meeting and Scientific Sessions held on Friday, 6th December and Saturday, 7th December, 1985 (1987) (0)
[The intracoronary infusion of superoxide dismutase during the initial liberation of oxygen free radicals induced by reperfusion. The effect on the infarct size after 60 minutes of coronary occlusion in the pig model]. (1991) (0)
Glycoprotein IIb/IIIa Receptor Blockade Improves Outcomes in Diabetic Patients Presenting With Unstable Angina/Non–ST-Elevation Myocardial Infarction Results From the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Cl (2000) (0)
UNSTABLE ANGINA Fibrinopeptide A and platelet factor levels in unstable angina pectoris (2005) (0)
Angiographic predictors of myocardial infarction: Independent value of stenosis symmetry and steep outflow angles (1996) (0)
Enhancing thrombolysis with adjunctive therapy (2004) (0)
High risk patient after recovery from myocardial infarction. (1983) (0)
Utility of post-procedure CK-MB ratio and ECG changes in clinical trials to predict early mortality following coronary bypass surgery (2000) (0)
[Prospective randomized study of the therapeutic action of propranolol compared to diltiazem in unstable stenocardia]. (1982) (0)
[Vasodilator agents in the treatment of acute and chronic cardiac insufficiency]. (1979) (0)
[Unstable angina at the crossroads]. (1987) (0)
Comparative Sensitivity ofExercise, ColdPressor andErgonovine Testing inProvoking Attacks ofVariant AnginainPatients withActive Disease (1983) (0)
Prognostic significance of refractory ischemia in unstable angina revisited (1998) (0)
1137-95 Demographics, treatment, and outcome of acute coronary syndromes: 17 years of experience in a tertiary care center (2004) (0)
[Calcium antagonists: pharmacological effects and therapeutic indications]. (1983) (0)
Glycoprotein IIb/IIIa receptor antagonism in patients with acute coronary syndromes and prior coronary artery bypass grafting: Results from PRISM PLUS (2003) (0)
Antithrombotic Therapy in Patients WithSaphenous Vein andInternal Mammary Artery Bypass Grafts (2015) (0)
Initial Experience Witha Direct Antithrombin, Hirulog, inUnstable Angina Anticoagulant, Antithrombotic, andClinical Effects (1993) (0)
epression , C-reactive Protein and Two-year Major dverse Cardiac Events in Men after Acute oronary Syndromes (2007) (0)
Blocking the terminal complement complex: Mismatch and misconception (2012) (0)
Effects of Antithrombotic Agents on Mortality and Nonfatal Cardiac Events (1994) (0)
Prognostic value of exercise testings soon after myocardial infarction (1980) (0)
High fasting insulin levels in patients with coronary artery disease and no known diabetes is a potent predictor of future cardiac events (2002) (0)
[Doppler echocardiography in the non-invasive assessment of the permeability of aorto-coronary bypass]. (1980) (0)
Can the geometry of a coronary stenosis predict occlusion and myocardial infarction in the following year (1996) (0)
significance Early postinfarction ischemia: clinical, angiographic, and prognostic (2011) (0)
Acute Coronary Syndromes. A Companion To Braunwald's Heart Disease (Online And Print) (2010) (0)
[Must the medical treatment of vasospastic angina be continued indefinitely?]. (1983) (0)
PATHOPHYSIOLOGY AND NATURAL HISTORY (2005) (0)
Platelet Glycoprotein IIb/IIIa Receptor Inhibition in Non–ST-Elevation Acute Coronary Syndromes Early Benefit During Medical Treatment Only, With Additional Protection During Percutaneous Coronary Intervention Brief Rapid Communication (1999) (0)
726 Acute Phase Inflammatory Biomarkers Add Little Predictive Value to Clinical Factors Plus NT-proBNP Among Patients With ST-Segment Elevation Myocardial Infarction: An Apex AMI Trial Substudy (2012) (0)
Heparin in unstable angina. Modalities for clinical benefit and pathophysiologic implications (1992) (0)
Coronary heart disease Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes (2006) (0)
Serial technetium 99m methoxyisobutylisonitrile mibi myocardial spect studies to assess reperfusion in patients with acute myocardial infarction (1989) (0)
Platelet activation in unstable angina is inhibited by r-hirudin, but not by heparin (1996) (0)
Pathophysiology of Unstable Angina Pectoris: Clinical, Angiographic and Therapeutic Observations (1988) (0)
Unstable angina and non-Q-wave myocardial infarction. Treatment beyond aspirin and heparin. (1999) (0)
Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes Clinical Investigation and Reports (2001) (0)
Chronic oral vasodilator therapy to control heart failure in postinfarction ventricular septal defect. (1979) (0)
[Prehospital fibrinolysis: a priority objective?]. (1992) (0)
Diabetes does not add to the increased six-month mortality associated with increase in CK-MB after percutaneous coronary intervention (2003) (0)
Comprar Acute Coronary Syndromes. A Companion To Braunwald's Heart Disease (Online And Print) | Pierre Theroux | 9781416049272 | Saunders (2010) (0)
Enoxaparin Treatment in Unstable Coronary Artery Disease: International Cost Savings (2002) (0)
[Coronary spasm and the ergonovine test. Clinical applications]. (1980) (0)
Effects ofThrombolytic Therapy Administered 6to24HoursAfterMyocardial Infarction on theSignal-Averaged ECG Results ofa Multicenter Randomized Trial (1994) (0)
Significance of exercise-induced ST depression in post-MI patients: Evaluation with Tc-99m sestamibi spect (1991) (0)
Action of nifedipine in ischemic heart disease. (1983) (0)
[Pulmonary capillary pressure studied with pulsed Doppler technic]. (1983) (0)
1118-102 Baseline white blood cell count and interleukin-6 levels provide complementary prognostic information in acute myocardial infarction: Results from the CARDINAL trial (2004) (0)
1098-82 Dynamic modeling of ST elevation acute myocardial infarction: Insights from COMMA (2004) (0)
Antithrombotic agents in coronary artery disease. (2001) (0)
Abstract 3216: The Serum of Pexelizumab-Treated ST-Segment Elevation MI Patients Reduces Complement Activation but not Cell Apoptosis (2007) (0)
[Normalization of the electrocardiogram in acute myocardial infarct]. (1977) (0)
Abstract 2360: Clopidogrel Loading with 600mg Double Bolus Achieves Better Platelet Inhibition than Conventional Regimens: Results from a Randomized Study. (2007) (0)
1006-41 Effect of Previous Treatment with Aspirin or Nitrates on the Clinical Manifestation of Acute Coronary Syndrome (1995) (0)
Management of unstable angina: tailoring therapeutic elements and intensity to risk profile (1998) (0)
[Secondary prevention following a myocardial infarct]. (1983) (0)
[Myocardial infarction with cardiogenic shock in the young adult (author's transl)]. (1980) (0)
Abstract 3567: Early Prediction of Left Ventricular Ejection Fraction 90 Days After STEMI Using NT-proBNP and Cardiac Magnetic Resonance Imaging (2009) (0)
Pilot study evaluating the use of cryoenergy for percutaneous myocardial revascularization (2002) (0)
The ergonovine test--to catch a leprechaun. (1983) (0)
Myocardial Ischemia and Infarction lopidogrel Inhibits Platelet-Leukocyte nteractions and Thrombin Receptor gonist Peptide-Induced Platelet Activation n Patients With an Acute Coronary Syndrome (2016) (0)
Non‐ST‐Segment Elevation Acute Coronary Syndromes: ACC/AHA Guidelines (2009) (0)
A computer-assisted lipid clinic (1990) (0)
[Coronary disease and calcium antagonists]. (1979) (0)
Glycoprotein IIb/IIIa inhibitors in unstable angina. (1997) (0)
Atherosclerosis / Coronary Heart Disease Short-term Cholesterol Lowering Decreases Size and Severity of Perfusion Abnormalities by Positron Emission Tomography After Dipyridamole in Patients With Coronary Artery Disease : A Potential Noninvasive Marker of Healing Coronary Endothelium (2005) (0)
[Complete medical records on a computer card: dream or reality?]. (1986) (0)
Predicting early coronary revascularization after an acute coronary syndrome (2003) (0)
Evaluation of prognosis 1 year after myocardial infarction. (1984) (0)
Significance of painless st segment depression during low level exercise testing early after acute myocardial infarction (1987) (0)
Lp(a) is related to complete obstruction of coronary arteries in men and to partial as well as complete obstruction in women (1991) (0)
[The future of fibrinolysis: from fibrinolytic treatment to reperfusion therapy]. (1992) (0)
Title : Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (0)
[Can the prognosis of myocardial infarction be determined at discharge from the hospital?]. (1987) (0)
Is the inhibition of the PAR-1 receptor with vorapaxar associated with anti-inflammatory effects in patients with symptomatic atherosclerosis: observations from TRA 2P-TIMI 50 (2013) (0)
TEMPORAL TRENDS OVER 15 YEARS IN CLINICAL TRIALS OF NON-ST ELEVATION ACUTE CORONARY SYNDROMES: MORE AGGRESSIVE TREATMENT YIELDS SIMILAR MORTALITY DESPITE HIGHER-RISK PROFILES (2010) (0)
Prognostic Value of Limited Exercise Testing before Hospital Discharge Following Myocardial Infarction (1981) (0)
Clinical and angiographic features and prognostic significance of early postinfarction angina with and without electrocardiographic signs of transient. Commentary (1992) (0)
Treatment Principles and Emerging Therapies in Acute Coronary Syndromes without ST-Segment Elevation (2011) (0)
[Usefulness and risk of ergonovine testing in Prinzmetal's angina]. (1979) (0)
Better evolution of acute myocardial infarction with enoxaparin versus unfractionated heparin (2003) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Pierre Théroux?

Pierre Théroux is affiliated with the following schools: